{
    "clinical_study": {
        "@rank": "68720", 
        "arm_group": [
            {
                "arm_group_label": "nevirapine and tenofovir/emtricitabine", 
                "arm_group_type": "Active Comparator", 
                "description": "nevirapine 200 mg twice daily combined  with tenofovir 300 mg/emtricitabine 200 mg (fixed-dose combination) once daily, per os for 96 weeks"
            }, 
            {
                "arm_group_label": "lopinavir/r and tenofovir/emtricitabine", 
                "arm_group_type": "Experimental", 
                "description": "ritonavir-boosted lopinavir 800/200 mg once daily or 400/100 mg twice daily combined with tenofovir 300 mg/emtricitabine 200 mg (fixed-dose combination) once daily, per os for 96 weeks"
            }, 
            {
                "arm_group_label": "Nevirapine and zidovudine/lamivudine", 
                "arm_group_type": "Active Comparator", 
                "description": "nevirapine 200 mg/zidovudine 300 mg/lamivudine 150 mg (fixed-dose combination) twice daily, per os for 96 weeks"
            }, 
            {
                "arm_group_label": "Lopinavir/r and zidovudine/lamivudine", 
                "arm_group_type": "Experimental", 
                "description": "ritonavir-boosted lopinavir 800/200 mg once daily or 400/100 mg once daily combined with zidovudine 300 mg/lamivudine 150 mg once daily, per os for 96 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "In resource-limited setting, concerns remain regarding the emergence of virologic failure\n      and high-level drug resistance mutations (DRM) during WHO recommended first-line\n      antiretroviral therapy (ART) with non-nucleoside reverse transcriptase inhibitors (NNRTI)\n      based regimens for Human immunodeficiency virus 1 (HIV1) infected patients. The study\n      hypothesis is that a boosted-protease inhibitor regimen has a better outcome than a\n      NNRTI-based regimen with a low genetic barrier to resistance.\n\n      The study is a randomized, multicenter, factorial trial (conducted in Congo), in treatment-\n      na\u00efve adults receiving for 96 weeks ritonavir- boosted lopinavir(LPV/r) or nevirapine (NVP)\n      each in combination with tenofovir (TDF) /emtricitabine (FTC) or zidovudine (ZDV)/lamivudine\n      (3TC). The primary end point is the incidence of therapeutic (clinical and/or\n      virologic)failure by study week 24."
        }, 
        "brief_title": "Nevirapine vs Ritonavir-boosted Lopinavir in ART Naive HIV-infected Adults in a Resource Limited Setting", 
        "completion_date": {
            "#text": "December 2011", 
            "@type": "Actual"
        }, 
        "condition": "HIV-1 Infection", 
        "condition_browse": {
            "mesh_term": "HIV Infections"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Antiretroviral-therapy na\u00efve HIV-1 infected Adults\n\n          -  WHO clinical stage 3 and CD4 <350/mm3 or\n\n          -  WHO clinical stage 4 or\n\n          -  CD4 cell count < 200/mm3\n\n          -  Negative pregnancy test\n\n        Exclusion Criteria:\n\n          -  Hemoglobin < 8.5 g/dL (female) or 9.0 g/dL (male)\n\n          -  Estimated Glomerular Filtration Rate < 50 ml/ minute (Cockcroft-Gault equation)\n\n          -  Hepatic transaminases (AST and ALT)> 3 x upper limit of normal\n\n          -  Active tuberculosis\n\n          -  Pregnancy\n\n          -  Females who are breastfeeding"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "425", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01772940", 
            "org_study_id": "Lubumbashi trial"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "nevirapine and tenofovir/emtricitabine", 
                    "Nevirapine and zidovudine/lamivudine"
                ], 
                "description": "Nevirapine 200 mg twice daily or 400 mg once daily per os during 96 weeks", 
                "intervention_name": "nevirapine", 
                "intervention_type": "Drug", 
                "other_name": "Viramune"
            }, 
            {
                "arm_group_label": [
                    "lopinavir/r and tenofovir/emtricitabine", 
                    "Lopinavir/r and zidovudine/lamivudine"
                ], 
                "description": "ritonavir-boosted lopinavir 800/200 mg once daily or 400/100 mg twice daily per os during 96 weeks", 
                "intervention_name": "ritonavir-boosted Lopinavir", 
                "intervention_type": "Drug", 
                "other_name": "Aluvia"
            }, 
            {
                "arm_group_label": [
                    "nevirapine and tenofovir/emtricitabine", 
                    "lopinavir/r and tenofovir/emtricitabine"
                ], 
                "description": "tenofovir 300 mg/emtricitabine 200 mg fixed-dose combination once daily, per os for 96 weeks", 
                "intervention_name": "Tenofovir/emtricitabine", 
                "intervention_type": "Drug", 
                "other_name": "Truvada"
            }, 
            {
                "arm_group_label": [
                    "Nevirapine and zidovudine/lamivudine", 
                    "Lopinavir/r and zidovudine/lamivudine"
                ], 
                "description": "zidovudine 300 mg/lamivudine 150 mg twice daily fixed-dose generic combination, per os for 96 weeks", 
                "intervention_name": "Zidovudine/lamivudine", 
                "intervention_type": "Drug", 
                "other_name": "Zidolam,combivir"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Zidovudine", 
                "Nevirapine", 
                "Lamivudine", 
                "Reverse Transcriptase Inhibitors", 
                "Tenofovir", 
                "Tenofovir disoproxil", 
                "Ritonavir", 
                "Lopinavir", 
                "Emtricitabine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "First-line therapy", 
            "Protease inhibitor", 
            "Non-Nucleoside Reverse transcriptase Inhibitor", 
            "Resource-limited setting"
        ], 
        "lastchanged_date": "August 22, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Lubumbashi", 
                    "country": "Congo", 
                    "state": "Katanga"
                }, 
                "name": "Cliniques Universitaires de Lubumbashi"
            }
        }, 
        "location_countries": {
            "country": "Congo"
        }, 
        "number_of_arms": "4", 
        "official_title": "Nevirapine vs Ritonavir-boosted Lopinavir in ART HIV-infected Adults in a Resource-limited Setting; a Randomized, Multicenter, Parallel Group Study", 
        "overall_official": {
            "affiliation": "Centre Hospitalier Universitaire Saint Pierre", 
            "last_name": "Nathan Clumeck, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Belgium: Ministry of Social Affairs, Public Health and the Environment", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "October 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The primary end point is the proportion of patients with therapeutic failure  defined as:\nthe occurence or relapse by week 24 of a World Health Organization (WHO) stage 4 or 3 event, or\ndeath by week 24, or\ndiscontinuation of study drugs due to toxicity at any time, or\nvirological failure defined as HIV-1 RNA > 1000 copies/ml by week 24", 
            "measure": "Incidence of therapeutic failure", 
            "safety_issue": "Yes", 
            "time_frame": "At week 48 with follow-up until week 96"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01772940"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Centre Hospitalier Universitaire Saint Pierre", 
            "investigator_full_name": "Clumeck Nathan", 
            "investigator_title": "Chief infectious diseases , Professor of Medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "The percentage of patients with HIV-1 RNA < 50 copies/ml", 
                "measure": "HIV-1 RNA viral load less than 50 copies/ml", 
                "safety_issue": "No", 
                "time_frame": "Through week 96"
            }, 
            {
                "description": "Cluster of differentiation 4 (CD4) cell count change from baseline", 
                "measure": "Immunologic response", 
                "safety_issue": "No", 
                "time_frame": "Through week 96"
            }, 
            {
                "measure": "HIV-1 resistance mutations", 
                "safety_issue": "No", 
                "time_frame": "At baseline and at the time of virologic failure"
            }, 
            {
                "description": "Incidence of adverse events and laboratory abnormalities", 
                "measure": "Safety and tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "Through week 96"
            }, 
            {
                "measure": "Changes in laboratory parameters", 
                "safety_issue": "No", 
                "time_frame": "Through week 96"
            }
        ], 
        "source": "Centre Hospitalier Universitaire Saint Pierre", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "University Hospital of Liege", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "PNMLS, Democratic Republic of Congo", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Pierre and Marie Curie University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University Paris 7 - Denis Diderot", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Gilead Sciences", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Abbott", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "Centre Hospitalier Universitaire Saint Pierre", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2008", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}